ATHE insider buying and SEC filings, explained
Alterity Therapeutics Ltd. · CIK 1131343
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$24K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 31, 2026 | Other purchase | David Allen Stamler (CEO and Director) bought 47,620 Listed option exp 31 Aug 2026 at $0.5000 ($24K), reported as a purchase (code P). Holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 8, 2026 |
| Aug 31, 2026 | Other purchase | Peter Ashley Marks (Director) bought 47,620 Listed option exp 31 Aug 2026 indirectly at $0.5000 ($24K), reported as a purchase (code P). Indirect holdings down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 8, 2026 |
| Aug 31, 2026 | Purchase (code P) | Peter Ashley Marks (Director) bought 47,620 shares indirectly at $0.5000 ($24K), reported as a purchase (code P). Indirect holdings up 33% to 191,340 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 8, 2026 |
2 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ATHE in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.